This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Ucbbiopharma Srl. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Gill Renner: Innovator in Cell Culture Methods
Introduction
Gill Renner, an accomplished inventor based in Slough, GB, has made significant contributions to the field of biotechnology. With a unique approach to cell culture methods, he focuses on utilizing limited amounts of cysteine and tryptophan in cell culture media for the production of recombinant proteins and antibodies. His innovative techniques aim to reduce heterogeneity in protein and antibody production, ultimately enhancing their efficacy.
Latest Patents
Renner holds a patent for his groundbreaking cell culture methods. The patent outlines his innovative approach that involves controlled conditions during the production of recombinant proteins. By adjusting amino acid concentrations, specifically cysteine and tryptophan, Renner's method successfully produces proteins and antibodies with reduced charge variants heterogeneity. This advancement has the potential to greatly impact the efficiency and reliability of biopharmaceuticals.
Career Highlights
Currently, Gill Renner is affiliated with UCB Biopharma, where his research focuses on optimizing bioprocesses for protein production. His work has positioned him as a key player in the biopharmaceutical industry, contributing to advancements that can enhance therapeutic outcomes. Renner’s patent is a testament to his commitment to innovation and excellence in his field.
Collaborations
Throughout his career, Renner has collaborated with talented individuals, including Bassem Ben Yahia and Laetitia Malphettes. These collaborations have fostered a rich exchange of ideas and expertise, leading to significant advancements in the area of recombinant protein production and cell culture techniques.
Conclusion
Gill Renner's contributions to the field of biotechnology through his innovative cell culture methods place him at the forefront of modern biopharmaceutical research. His patent represents a considerable step forward in producing recombinant proteins with enhanced consistency and efficacy. As he continues his work at UCB Biopharma, the industry can anticipate further innovations that will shape the future of biotechnology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile